Johnson & Johnson (JNJ) received Breakthrough Therapy Designation from the FDA for its multiple myeloma candidate talquetamab, reinforcing its position in the healthcare market. Despite this positive development and a record of modest EPS beats over the past quarters, the company faces a legal challenge from Oklahoma, which has filed a lawsuit against it. J&J is characterized as a safe investment due to its steady financial fundamentals and reliable cash flows, but ongoing supply complications in its consumer unit may impact overall sales.
“FDA · granted · Breakthrough Therapy Designation · to J&J's multiple myeloma candidate, talquetamab”
“Top stocks to buy and watch · include · AutoZone and Johnson & Johnson · true”
“Top stocks to buy and watch · include · Johnson & Johnson”
“Johnson & Johnson (JNJ) · underpin · safety · steady fundamentals and steady growth”
“Johnson & Johnson (JNJ) · is characterized as · safe”
“Johnson & Johnson (JNJ) · has had · modest EPS beats · in each of the last four quarters”
“Johnson & Johnson · exudes · safety · true”
“Johnson & Johnson (JNJ) · is characterized as · a safe stock”
“Johnson & Johnson (JNJ) · has · modest EPS beats · in each of the last four quarters”
“Oklahoma · sued · Johnson & Johnson · separately”
“Johnson & Johnson (JNJ) · provides · steady fundamentals and steady growth · .”
“Johnson & Johnson (JNJ) · exudes · safety · not just for the brands it produces”
